BioProcessing - Informa Connect

@BioprocessIC

The official account for the Informa Connect bioprocessing and manufacturing portfolio - your home for events, content and training.

Vrijeme pridruživanja: ožujak 2009.

Tweetovi

Blokirali ste korisnika/cu @BioprocessIC

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BioprocessIC

  1. Behnam Ahmadian, Global Head of Process Development at Lonza, discusses the scaling of manufacturing, process development challenges, and the latest for therapies in this exclusive interview

    Poništi
  2. CAR-T and T-cell receptor therapies are some of the most exciting emerging therapies on the market today. This whitepaper discusses recent developments in CAR and TCR and the overlap with engineering

    Poništi
  3. How are leading biotech and pharma organizations successfully implementing initiatives? Here are 6 best practices chosen by Edie Stringfellow

    Poništi
  4. On the road to successful discovery, the search for validated targets becomes more challenging. This whitepaper examines the latest innovations addressing the current practical challenges in antibody discovery.

    Poništi
  5. When developing a new therapy how do you keep in complete control of its manufacturing? This whitepaper looks at what to consider - whatever path you take.

    Poništi
  6. 62% of respondents their cell and therapies both internally and externally

    Poništi
  7. How can you navigate the regulatory maze to get peptide, oligonucleotide and mRNA therapies to market? This whitepaper presents successful strategies & case studies.

    Poništi
  8. Viral vector vaccines hold great promise for confronting new, complex pathogens. Three industry experts discuss the challenges of manufacturing viral vector in this eBook

    Poništi
  9. Bioprinting is ready to create tissue products with high commercial and therapeutic value, but there are still key development hurdles to make the viable for the industry

    Poništi
  10. As the search for validated targets becomes more challenging, unconventional strategies are becoming more significant. This whitepaper examines the latest innovations and current practical challenges in discovery

    Poništi
  11. Authors from GSK and MockV Solutions describe the use of a noninfectious particle as an economical spiking surrogate in this deep dive

    Poništi
  12. The high costs of cell therapy puts it out of reach for many cancer patients. How can it be made more affordable? We asked three industry experts

    Poništi
  13. Heidelberg-based have created tumor-targeted oncolytic virus vaccines using encoded bispecific T-cell engagers. In this recorded webinar, Christine Engeland, MD, PhD explains their journey.

    Poništi
  14. What’s the recipe for getting peptide, oligonucleotide and mRNA treatments approved? This whitepaper explores how to navigate the current regulatory frameworks.

    Poništi
  15. BioProcess International’s editors share their experiences of the 2019 BPI US conference in Boston, focusing attention on elements that are driving in the industry

    Poništi
  16. Behnam Ahmadian, Global Head of Process Development at Lonza, discusses the scaling of manufacturing, process development challenges, and the latest for therapies in this exclusive interview

    Poništi
  17. How are leading biotech and pharma organizations successfully implementing initiatives? Here are 6 best practices chosen by Edie Stringfellow

    Poništi
  18. BioProcess International managing editor Maribel Rios rounds up the latest technologies that demonstrate the bioprocessing industry’s dedication to finding new ways to help manufacturers shorten time to market

    Poništi
  19. As the search for validated targets becomes more challenging, unconventional strategies are becoming more significant. This whitepaper examines the latest innovations and current practical challenges in discovery

    Poništi
  20. Can viruses be used to create tumor-targeted vaccines? In an on-demand webinar, Christine Engeland, MD, PhD explains how they have done just that, by encoding bispecific T-cell engagers within measles virus vectors.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·